Page 2 - ஷில்பா மருத்துவ வரையறுக்கப்பட்டவை News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Indian Shilpa Medicare signs deal to produce Sputnik V It was noted that production of the Sputnik V two-component vaccine is planned to be 50 mln doses within the first 12 months from the date of commercialization - that is 50 mln of the first component and 50 mln of the second component © EPA-EFE/JAGADEESH NV NEW DELHI, May 17. /TASS/. Indian pharmaceutical company Shilpa Medicare Limited entered into an agreement with Dr. Reddy s Laboratories on the production and supply of the Russian-developed Sputnik V vaccine, the company reported on Monday in a press release. According to the statement, the company, through its subsidiary Shilpa Biologicals Private Limited (SBPL), has entered into a final three-year agreement with Dr. Reddy s Laboratories Limited for the production and supply of Sputnik V vaccine from its integrated biological research and development center in Dharwad, Karnataka.

United kingdomUniversity of oxfordShilpa medicareWorld health organizationShilpa biologicals private limitedReddy laboratoriesRussian direct investment fundShilpa medicare limitedLaboratories limitedSputnik lightஒன்றுபட்டது கிஂக்டம்பல்கலைக்கழகம் ஆஃப் ஆக்ஸ்ஃபர்ட்ஷில்பா மருத்துவஉலகம் ஆரோக்கியம் ஆர்கநைஸேஶந்ஷில்பா உயிரியல் ப்ரைவேட் வரையறுக்கப்பட்டவைசிவப்பு ஆய்வகங்கள்